bioAffinity Technologies, Inc. (BIAFW)

Every figure this model derived for BIAFW, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 91,988 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 2,429,719 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 3,865,280 AssetsCurrent 2026-06-30
current liabilities 2,680,906 LiabilitiesCurrent 2026-06-30
equity 3,768,797 StockholdersEquity 2026-06-30
interest expense 44,837 InterestExpenseNonoperating 2026-06-30
ocf -11,468,205 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 5,900,985 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 932,532 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up BIAFW on one particular measure came for.

RatioValue
cash operating margin-187.02
current ratio1.46
current ratio reported1.44
deferred revenue growth27.6
dilution pct326.26
fcf margin-195.9
growth cv1.4
interest cover-276.15
operating margin-209.82
owner earnings margin-211.71
revenue growth-23.17
revenue growth per share-81.98
roic-505.06
rule of 40-233.0
sbc pct revenue15.8

What to be careful about

What this model itself distrusts about BIAFW's figures. Written by the derivation as it ran, not added afterwards.